Fortrea Holdings Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Anshul Thakral
- Full Time Employees
- 14,000
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8 Moore Drive Durham NC United States of America 27713
- IPO Date
- Jun 20, 2023
- CIK
- 0001965040
- Website
- fortrea.com
- Similar Companies
- Business
- Fortrea Holdings Inc. (Nasdaq: FTRE) is a leading global contract research organization (CRO) that provides comprehensive clinical development solutions to biopharmaceutical, biotechnology, and medical device companies worldwide. The company offers Phase I-IV clinical trial management; clinical pharmacology services, including first-in-human and exploratory studies; drug development consulting; regulatory guidance; pharmacovigilance; medical writing; data management and biostatistics; patient recruitment; site management; and specialized expertise in oncology, rare diseases, central nervous system disorders, neurodegenerative conditions, and cell and gene therapies. Fortrea delivers these services through flexible models comprising full-service outsourcing (FSO), functional service provider (FSP), and hybrid structures, supported by clinical research units in the U.S. and U.K., cGMP pharmacies, and operations across 90 countries. Incorporated in 2023 following its spin-off from Labcorp in July 2023, Fortrea traces its origins to 1968 through predecessors including Covance and Corning Lab Services, and is headquartered at 8 Moore Drive in Durham, North Carolina. In June 2024, Fortrea completed the divestiture of its Endpoint Clinical (interactive response technology and clinical supply chain solutions) and Fortrea Patient Access (patient access services) businesses to Arsenal Capital Partners, enabling a sharpened focus as a pure-play clinical CRO. Most recently, in 2025, Fortrea announced a strategic collaboration with SCTbio to integrate clinical development with cGMP manufacturing for cell therapy innovators, alongside recognition as a leader in pharmacovigilance operations per the PEAK Matrix Assessment 2025.
Company News
3 Top Small-Cap Stocks With Market-Beating Momentum
MindWalk (NASDAQ:HYFT) & Fortrea (NASDAQ:FTRE) Head to Head Contrast
Ausbil Investment Management Ltd Decreases Stake in Fortrea Holdings Inc. $FTRE
Fortrea (NASDAQ:FTRE) Reaches New 52-Week High – What’s Next?
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
Fortrea Holdings Inc. (NASDAQ:FTRE) Stock Rated “Hold” by Sell-Side Brokerages
Financial Survey: Fortrea (NASDAQ:FTRE) vs. Bullfrog AI (NASDAQ:BFRG)
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fortrea to Participate in September Investor Conferences
Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion
Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials
Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue
Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know
FTRE vs. ARGX: Which Stock Is the Better Value Option?
Best Momentum Stock to Buy for July 31st
Fortrea Holdings Inc. (FTRE) Is Attractively Priced Despite Fast-paced Momentum
Fortrea Holdings Inc. (FTRE) Q2 2026 Earnings Call Transcript
Fortrea Q2 Earnings Call Highlights
Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue Estimates
Fortrea Reports Second Quarter 2026 Results